Dr Andrew Retter, Chief Medical Officer at Volition said: "We are excited to report the findings of this large-scale independent clinical study, the culmination of many years work. Nu.Q® NETs ...
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with a leading pharmaceutical company to utilize Volition's ...
A live question and answer session will follow the formal presentations. About Dr. Andrew Retter Andrew Retter, BSc (Hons), MBBS, FRCP, FRCPath (Haem), DICM is Consultant in Critical Care ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results